KAM
BPMC

Kazazian Asset Management’s Blueprint Medicines BPMC Stock Holding History

Kazazian Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,800
Closed -$419K – 65
2024
Q4 		$419K Buy
+4,800
New +$440K 0.32% 35

Other funds holding BPMC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Kazazian Asset Management's BPMC Position: Q3 2019 in Review

Kazazian Asset Management held its Blueprint Medicines (BPMC) position steady in Q3 2019 at 7,662 shares worth $563K. The position accounts for 0.76% of the portfolio, ranked #32.

Kazazian Asset Management first reported a position in BPMC in Q2 2017 and has held it in 10 quarters since. The position peaked at $2.63M in Q1 2018. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

  • Kazazian Asset Management held 7,662 shares of Blueprint Medicines worth $563K as of Q3 2019.
  • Kazazian Asset Management left its Blueprint Medicines share count unchanged in Q3 2019.
  • Blueprint Medicines made up 0.76% of Kazazian Asset Management's portfolio in Q3 2019, its #32 holding.
  • Kazazian Asset Management first reported a position in Blueprint Medicines in Q2 2017 and has held it in 10 quarters since.
  • Kazazian Asset Management's Blueprint Medicines position peaked at $2.63M in Q1 2018.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Kazazian Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.